Gap Junction Enhancer Increases Efficacy of Cisplatin to Attenuate Mammary Tumor Growth

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Shishido, Stephanie N ^a   Nguyen, Thu A ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 8 [(2 FURANYLMETHYL)AMINO] 4 METHYL 5 (3 TRIFLUOROMETHYL PHENYLOXY) QUINOLINE DERIVATIVE; 6 METHOXY 8 [(3 AMINOPROPYL)AMINO] 4 METHYL 5 (3 TRIFLUOROMETHYL PHENYLOXY) QUINOLINE DERIVATIVE; CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; CONNEXIN 26; CONNEXIN 32; CONNEXIN 43; GAP JUNCTION PROTEIN; QUINOLINE DERIVATIVE; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GAP JUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; GAP JUNCTIONS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS;

EID: 84866377163     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044963     Document Type: Article

References (40)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Wilgenbus KK, Kirkpatrick CJ, Knuechel R, Willecke K, Traub O, (1992) Expression of Cx26, Cx32 and Cx43 gap junction proteins in normal and neoplastic human tissues. Int J Cancer 51: 522-529.
3. Loewenstein WR, (1979) Junctional intercellular communication and the control of growth. Biochim Biophys Acta 560: 1-65.
4. Yamasaki H, Naus CC, (1996) Role of connexin genes in growth control. Carcinogenesis 17: 1199-1213.
5. Simpson I, Rose B, Loewenstein WR, (1977) Size limit of molecules permeating the junctional membrane channels. Science 195: 294-296.
6. Loewenstein WR, Kanno Y, (1966) Intercellular communication and the control of tissue growth: lack of communication between cancer cells. Nature 209: 1248-1249.
7. Shi A, Nguyen TA, Battina SK, Rana S, Takemoto DJ, et al. (2008) Synthesis and anti-breast cancer activities of substituted quinolines. Bioorg Med Chem Lett 18: 3364-3368.
8. Gakhar G, Ohira T, Shi AB, Hua DH, Nguyen TA, (2008) Antitumor Effect of Substituted Quinolines in Breast Cancer Cells. Drug Development Research 69: 526-534.
9. Heiniger B, Gakhar G, Prasain K, Hua DH, Nguyen TA, (2010) Second-generation Substituted Quinolines as Anticancer Drugs for Breast Cancer. Anticancer Research 30: 3927-3932.
10. Leonard BJ, Ecclesto E, Jones D, Todd P, Walpole A (1971) Antileukaemic and Nephrotoxic Properties of Platinum Compounds. Nature 234: 43.
11. Zamble DB, Lippard SJ, (1995) Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 20: 435-439.
12. Eastman A, (1987) The Formation, Isolation and Characterization of DNA Adducts Produced by Anticancer Platinum Complexes. Pharmacology & Therapeutics 34: 155-166.
13. Pabla N, Dong Z, (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73: 994-1007.
14. Jensen R, Glazer PM, (2004) Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions. Proceedings of the National Academy of Sciences of the United States of America 101: 6134-6139.
15. He B, Tong XH, Wang LZ, Wang Q, Ye H, et al. (2009) Tramadol and Flurbiprofen Depress the Cytotoxicity of Cisplatin via Their Effects on Gap Junctions. Clinical Cancer Research 15: 5803-5810.
16. Tanaka M, Grossman HB, (2001) Connexin 26 gene therapy of human bladder cancer: induction of growth suppression, apoptosis, and synergy with Cisplatin. Hum Gene Ther 12: 2225-2236.
17. Willecke K, Eiberger J, Degen J, Eckardt D, Romualdi A, et al. (2002) Structural and functional diversity of connexin genes in the mouse and human genome. Biol Chem 383: 725-737.
18. Pozzi A, Risek B, Kiang DT, Gilula NB, Kumar NM, (1995) Analysis of multiple gap junction gene products in the rodent and human mammary gland. Experimental Cell Research 220: 212-219.
19. Kroemer G, Reed JC, (2000) Mitochondrial control of cell death. Nat Med 6: 513-519.
20. Ashkenazi A, Dixit VM, (1998) Death receptors: signaling and modulation. Science 281: 1305-1308.
21. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, et al. (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152: 43-49.
22. Altieri DC, (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54.
23. Ambrosini G, Adida C, Altieri DC, (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921.
24. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC, (2004) Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. Journal of Clinical Investigation 114: 1117-1127.
25. Jiang W, Kahn SM, Zhou P, Zhang YJ, Cacace AM, et al. (1993) Overexpression of Cyclin D1 in Rat Fibroblasts Causes Abnormalities in Growth-Control, Cell-Cycle Progression and Gene-Expression. Oncogene 8: 3447-3457.
26. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, et al. (1995) Human Mig chemokine: biochemical and functional characterization. Journal of Experimental Medicine 182: 1301-1314.
27. Wang Q, You T, Yuan D, Han X, Hong X, et al. (2010) Cisplatin and oxaliplatin inhibit gap junctional communication by direct action and by reduction of connexin expression, thereby counteracting cytotoxic efficacy. J Pharmacol Exp Ther 333: 903-911.
28. Kuwahara D, Tsutsumi K, Kobayashi T, Hasunuma T, Nishioka K, (2000) Caspase-9 regulates cisplatin-induced apoptosis in human head and neck squamous cell carcinoma cells. Cancer Letters 148: 65-71.
29. Ferlini C, DiCesare S, Rainaldi G, Malorni W, Samoggia P, et al. (1996) Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytometry 24: 106-115.
30. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, et al. (1997) Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis). Cytometry 27: 1-20.
31. Liu B, Wang Q, Yuan DD, Hong XT, Tao L, (2011) Berberine potentizes apoptosis induced by X-rays irradiation probably through modulation of gap junctions. Chin Med J (Engl) 124: 1221-1228.
32. Kadle R, Zhang JT, Nicholson BJ, (1991) Tissue-Specific Distribution of Differentially Phosphorylated Forms of Cx43. Molecular and Cellular Biology 11: 363-369.
33. Peterson-Roth E, Brdlik CM, Glazer PM, (2009) Src-Induced cisplatin resistance mediated by cell-to-cell communication. Cancer Research 69: 3619-3624.
34. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, et al. (2003) Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 88: 73-79.
35. Mazurenko NN, Kogan EA, Zborovskaya IB, Kisseljov FL, (1992) Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer 28: 372-377.
36. Bu RF, Purushotham KR, Kerr M, Tao Z, Jonsson R, et al. (1996) Alterations in the level of phosphotyrosine signal transduction constituents in human parotid tumors. Proceedings of the Society for Experimental Biology and Medicine 211: 257-264.
37. Masumoto N, Nakano S, Fujishima H, Kohno K, Niho Y, (1999) v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells. Int J Cancer 80: 731-737.
38. Pengetnze Y, Steed M, Roby KF, Terranova PF, Taylor CC, (2003) Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun 309: 377-383.
39. Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, et al. (2006) Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Cancer Chemother Pharmacol 58: 577-584.
40. Madias NE, Harrington JT, (1978) Platinum nephrotoxicity. Am J Med 65: 307-314.